Treatment of lung<unk> -cell<unk>  depends on many factors including stage, resectability, performance status and genomic alterations acquired by the individual tumor. Therapy of early-stage SCC mimics that of other histologic types of NSCLC. Early stage (I, II and IIIA) lung SCC are typically resected surgically, and cytotoxic chemotherapy and/or radiation may be used as an adjuvant therapy following surgery. On the other hand, advanced, metastatic or recurrent lung SCC are given first-line systemic therapy with a palliative (i.e., noncurative) intent consisting of cytotoxic chemotherapy, most commonly a platinum-based doublet. Either cisplatin or carboplatin is used as the platinum backbone. Development of targeted therapies has been less rapid for lung SCC with respect to adenocarcinoma, as ALK rearrangements and EGFR mutations targetable with receptor tyrosine kinase inhibitors are much less frequent in the former compared to the latter. Immunotherapy is showing promising results for NSCLC, and anti-PD-1 agent nivolumab has been approved by the US Food and Drug Administration (FDA) for lung SCC.
Squamous-cell carcinoma of the lung
Sarcomatoid carcinoma of the lung
Adenocarcinoma of the lung
Giant-cell carcinoma of the lung
Pulmonary sclerosing pneumocytoma
Acinic cell carcinoma of the lung
Non-small-cell lung carcinoma
Large-cell lung carcinoma